04.03.24
Sabinsa, the multinational health science company founded by the late Dr. Muhammed Majeed 36 years ago, named Dr. Anju Majeed as Sami-Sabinsa Group Executive Chairperson, assuming the role her father held until his death on March 13, 2024. The news was first reported in Happi last month.
The company also announced Shaheen Majeed as global managing director & CEO.
Anju Majeed PhD, received Bachelor’s and Master’s degrees from Rutgers University in microbiology and molecular genetics, a further Master’s in biological sciences from Johns Hopkins and her PhD in Microbiology from Bharathidasan University. She was a National Institute of Health Research Fellow from 2001-2005. She has expertise in SAS and clinical SAS database management. Anju is based in the Sami-Sabinsa Group headquarters in Bengaluru, India.
A highly motivated person, she drives new technologies and processes, develops new product formulations, and creates scalable manufacturing processes for Sami, which are further used in clinical trials through all phases of development. As Sami-Sabinsa group director and senior scientist, she worked closely with analytical and formulation scientists and operates via multifunctional, global teams, including API manufacturing, process R&D, pre-formulation and pilot plant operations. The passion that drives her comes from perseverance and a strong desire to contribute to the society, according to the company.
Shaheen Majeed has been named to the board of directors of the Sami-Sabinsa Group. He heads the Sami-Sabinsa Group as global managing director & chief executive officer.
For 25 years, Shaheen was instrumental in building Sabinsa into a global leader with a vast ingredient portfolio. He held various positions of increasing responsibilities with Sabinsa, including roles in sales, supply chain, manufacturing and global marketing, culminating in four years as president worldwide. He was instrumental in executing the global strategies, expanding the company's footprints, ensuring cGMP and regulatory compliance, guiding several clinical studies through the publishing process, and he currently holds 46 US and international patents. He previously served as CEO of three subsidiaries of BGG World: HB Natural Ingredients, BGG Americas and Algae Health Sciences.
The company also announced Shaheen Majeed as global managing director & CEO.
Anju Majeed PhD, received Bachelor’s and Master’s degrees from Rutgers University in microbiology and molecular genetics, a further Master’s in biological sciences from Johns Hopkins and her PhD in Microbiology from Bharathidasan University. She was a National Institute of Health Research Fellow from 2001-2005. She has expertise in SAS and clinical SAS database management. Anju is based in the Sami-Sabinsa Group headquarters in Bengaluru, India.
A highly motivated person, she drives new technologies and processes, develops new product formulations, and creates scalable manufacturing processes for Sami, which are further used in clinical trials through all phases of development. As Sami-Sabinsa group director and senior scientist, she worked closely with analytical and formulation scientists and operates via multifunctional, global teams, including API manufacturing, process R&D, pre-formulation and pilot plant operations. The passion that drives her comes from perseverance and a strong desire to contribute to the society, according to the company.
Shaheen Majeed has been named to the board of directors of the Sami-Sabinsa Group. He heads the Sami-Sabinsa Group as global managing director & chief executive officer.
For 25 years, Shaheen was instrumental in building Sabinsa into a global leader with a vast ingredient portfolio. He held various positions of increasing responsibilities with Sabinsa, including roles in sales, supply chain, manufacturing and global marketing, culminating in four years as president worldwide. He was instrumental in executing the global strategies, expanding the company's footprints, ensuring cGMP and regulatory compliance, guiding several clinical studies through the publishing process, and he currently holds 46 US and international patents. He previously served as CEO of three subsidiaries of BGG World: HB Natural Ingredients, BGG Americas and Algae Health Sciences.